amifostine anhydrous has been researched along with Carcinoma in 11 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Grade 2 proctitis was noted in 18." | 1.38 | Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer. ( Abatzoglou, I; Koukourakis, MI; Panteliadou, M; Papadopoulou, A; Sismanidou, K; Touloupidis, S, 2012) |
| " Skin reactions, four different kidney assays, regrowth delay and local control of tumours have been used to construct dose-response curves from which the degree of radioprotection can be quantified as a protection factor." | 1.27 | Fractionation studies with WR-2721: normal tissues and tumour. ( Denekamp, J; Rojas, A; Smith, KA; Soranson, JA; Stewart, FA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koukourakis, MI | 2 |
| Tsoutsou, PG | 1 |
| Karpouzis, A | 1 |
| Tsiarkatsi, M | 1 |
| Karapantzos, I | 1 |
| Daniilidis, V | 1 |
| Kouskoukis, C | 1 |
| Bourhis, J | 1 |
| Blanchard, P | 1 |
| Maillard, E | 1 |
| Brizel, DM | 1 |
| Movsas, B | 1 |
| Buentzel, J | 1 |
| Langendijk, JA | 1 |
| Komaki, R | 1 |
| Swan Leong, S | 1 |
| Levendag, P | 1 |
| Pignon, JP | 1 |
| Small, W | 1 |
| Winter, K | 1 |
| Levenback, C | 1 |
| Iyer, R | 1 |
| Hymes, SR | 1 |
| Jhingran, A | 1 |
| Gaffney, D | 1 |
| Erickson, B | 1 |
| Greven, K | 1 |
| Papadopoulou, A | 1 |
| Abatzoglou, I | 1 |
| Panteliadou, M | 1 |
| Sismanidou, K | 1 |
| Touloupidis, S | 1 |
| Astudillo, L | 1 |
| Maachi, B | 1 |
| Benyoucef, A | 1 |
| Game, X | 1 |
| Rives, M | 1 |
| Bachaud, JM | 1 |
| Milas, L | 1 |
| Hunter, N | 1 |
| Ito, H | 1 |
| Peters, LJ | 1 |
| Shapiro, JD | 1 |
| Rothenberg, ML | 1 |
| Sarosy, GA | 1 |
| Steinberg, SM | 1 |
| Adamo, DO | 1 |
| Reed, E | 1 |
| Ozols, RF | 1 |
| Kohn, EC | 1 |
| Ng, TY | 1 |
| Ngan, HY | 1 |
| Cheng, DK | 1 |
| Wong, LC | 1 |
| Nagy, P | 1 |
| Kádasi, L | 1 |
| Vaira, M | 1 |
| Barone, R | 1 |
| Aghemo, B | 1 |
| Mioli, PR | 1 |
| De Simone, M | 1 |
| Rojas, A | 1 |
| Stewart, FA | 1 |
| Soranson, JA | 1 |
| Smith, KA | 1 |
| Denekamp, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes[NCT00012012] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The second part of this study (second arm) was designed to detect a 40% relative reduction (absolute from 77% to 46%) in the acute grade 3/4 toxicity (excluding grade 3 leukopenia) rate, with the addition of amifostine. A one-sided alpha of 0.05 and 80% power required 16 evaluable patients to detect the hypothesized difference. If ≤ 8 had the toxicity, it would be concluded that adding amifostine decreased this toxicity rate by at least 40%. (NCT00012012)
Timeframe: From start of treatment to 90 days
| Intervention | participants (Number) |
|---|---|
| Radiation Therapy Plus Cisplatin and Amifostine | 13 |
To determine the feasibility and tolerance of extended-field external radiotherapy to the pelvis and para-aortic region and intracavitary irradiation combined with weekly cisplatin using the rate of acute grade 3/4 toxicity rate (excluding grade 3 leukopenia). The first part of this study was designed to determine the acute grade 3/4 toxicity rate (excluding grade 3 leukopenia), to have a starting point for the second part (second arm) of the study. (NCT00012012)
Timeframe: From start of treatment to 90 days
| Intervention | percentage of participants (Number) |
|---|---|
| Radiation Therapy Plus Cisplatin | 81 |
1 review available for amifostine anhydrous and Carcinoma
| Article | Year |
|---|---|
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-S | 2011 |
4 trials available for amifostine anhydrous and Carcinoma
| Article | Year |
|---|---|
Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Brachytherapy; Carcinoma; Cisplatin; Female; Humans; | 2011 |
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclo | 1998 |
[Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Topics: Amifostine; Antineoplastic Agents; Carcinoma; Cisplatin; Humans; Hyperthermia, Induced; Intraoperati | 2001 |
6 other studies available for amifostine anhydrous and Carcinoma
| Article | Year |
|---|---|
Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
Topics: Aged; Amifostine; Carcinoma; Cytoprotection; Diarrhea; Dysuria; Humans; Male; Middle Aged; Proctitis | 2012 |
Stevens-Johnson syndrome after amifostine during radiotherapy.
Topics: Amifostine; Carcinoma; Humans; Injections, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Rad | 2004 |
Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721.
Topics: Amifostine; Animals; Carcinoma; Dose-Response Relationship, Radiation; Female; Fibrosarcoma; Male; M | 1984 |
The effect of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines.
Topics: Amifostine; Antineoplastic Agents; Carcinoma; Drug Interactions; Female; Humans; Ovarian Neoplasms; | 1999 |
[Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; | 2000 |
Fractionation studies with WR-2721: normal tissues and tumour.
Topics: Amifostine; Animals; Carcinoma; Female; Kidney; Lethal Dose 50; Mammary Neoplasms, Experimental; Mic | 1986 |